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(I) Introduction
It is now well-appreciated that marrow is a complex tissue composed of two distinct but interdependent compartments: the hematopoietic system and the bone marrow stroma. Investigations into the cooperative interactions between these two compartments have shown that hematopoietic cells influence the activity of the stromal compartment, and in addition to serving as a mechanical support for differentiating hematopoietic cells, the bone marrow stroma also expresses cell-signaling factors that participate in the development of mature blood cells. A vast body of literature concerning hematopoietic cell transplantation exists; however, much less attention has been paid to transplantation of bone marrow stroma. Here, we review the development and functional nature of bone marrow stroma, and detail studies on the transplantation of bone marrow stromal cells (BMSCs) for the regeneration of skeletal elements.
(11) The Bone Marrow Stroma in vivo "Stroma", in ancient Greek, means the physical substrate, or something upon which one rests or lies. Hematopoietic cells proliferate, differentiate, and mature upon a meshwork of cell processes and surfaces that together comprise the bone marrow stromal scaffold. In mammals, hematopoiesis is an extravascular process, and therefore is supported by an extravascular marrow stroma as well. The stroma includes all cell types that (1) are located between the outer surfaces of marrow blood vessels and the bone surfaces which encase the hematopoietic space and tissue, and (2) are not of the hematopoietic lineage, and these include marrow adipocytes, Westen-Bainton cells, bone-lining cells (inactive osteoblasts), and osteoblastic cells.
Westen-Bainton cells (Westen and Bainton, 1979; are specialized, hematopoiesis-supporting cells noted for, and defined by, the expression of high levels of membrane-associated alkaline phos-phatase activity, the time-honored marker of osteogenic commitment in bone development. These cells are referred to by a variety of descriptive terms (reticular cells, adventitial reticular cells, and stromal fibroblasts). The diversity in nomenclature, together with the remarkably elusive morphology of the cells themselves, contributes to the vagueness of our concept of the marrow stroma as a tissue. Therefore, the eponymic designation (Westen-Bainton) and a functional phenotypic trait (alkaline phosphatase activity, ALP) best substitute for these terms. In the post-natal marrow, these cells provide an adventitial (outer) coating to the sinusoid wall on which they spread with no intervening physically continuous basement membrane. Extensive, elongated, and attenuated cell processes characterize their morphology ("reticular"). These cells express collagen types I and III, osteonectin, and are considered "fibroblastic" in nature. It should be noted, however, that the collagen fiber content is extremely sparse in the normal bone marrow.
In development, Westen-Bainton (WB) cells populate the primitive marrow spaces prior to the local appearance of hematopoietic cells. They originate from the primitive osteogenic periosteum of developing bones and co-migrate, along with ingrowing blood vessels, to the interior of developing bones, where they actively proliferate and provide the reservoir of immediate osteogenic precursors (proliferating pre-osteoblasts) for pre-natal osteogenesis (Bianco and Bonucci, 1991; Riminucci et al., 1997) . When the primitive, nonhematopoietic marrow is seeded with blood-borne hematopoietic stem cells, a close relationship is established between developing blood cells and WB (stromal) cells. interestingly, endothelium-specific, carbohydratebinding receptors termed selectins are expressed in stromal cells (PJ Simmons, personal communication) , and likely mediate the physical interaction between maturing blood cells and an extravascular stroma. In the postnatal marrow in situ, WB cells generate and maintain the hematopoietic micro-environment. Indiscernible in routine histological material, and elusive even by electron microscopy, WB cells can be conveniently imaged in situ by ALP cytochemistry and confocal reflectance microscopy Boyde, 1989, 1993) , which allows for documentation of their 3-D shape, mutual arrangement, and physical association with maturing hematopoietic cells. Their association with the adventitia of small arteries and the outer surfaces of sinusoids in the post-natal marrow reflects the developmental coupling of osteogenesis and vascularity.
Several pathological conditions in the bone/bone marrow organ can be seen as diseases of WB cells-that is, of osteogenic marrow stromal cells. In the developing marrow, cells identified as the major parathyroid-hormone-binding cell type in vivo (Rouleau et at., 1988) are indistinguishable from WB cells. Interestingly, bone disease in human hyperparathyroidism is characterized by localized increases in WB cells, which result in the socalled "endosteal fibrosis" (Bianco and Bonucci, 1991) . Likewise, in the McCune-Albright syndrome, where stimulation of the relevant signal transduction pathway is due to mutated, overactive Gsa, the fibrous dysplasia of bone results from an increase in number of WB cells (Riminucci et al., 1997) . Weston-Bainton cells also proliferate and mature to bone-forming cells responsible for osteosclerosis in cancer metastasis to the marrow (P Bianco, unpublished data).
In post-natal human marrow, Weston-Bainton cells demonstrate characteristics of pre-adipocytes (Bianco et al., 1988 . Local peritrabecular adipose conversion of WB cells occurs in involutional osteoporosis. Thus, age-related changes in the size and functional properties of the WB cell compartment in the post-natal marrow represent an obvious direction for future investigation.
As pre-osteogenic and pre-adipogenic cells, WB cells are multipotential elements in the post-natal marrow. As an integral part of the hematopoietic micro-environment, they are also endowed with a phenotype and function that are differentiated in their own right. This emphasizes how retention of the potential for multiple differentiation (a "stem cell" characteristic) may be associated with differentiated function in the stromal system. This represents a major biological divergence from the hematopoietic system, from which the very concept of the stromal system was derived by analogy.
(111) Bone Marrow Stromal Cells in vitro To date, the identity of the in vitro counterpart of the bone marrow stroma observed in vivo (Westen-Bainton cells) is not entirely clear. However, when bone marrow is plated in vitro, adherent cells of non-hematopoietic origin (i.e., not macrophages) proliferate and exhibit many of the characteristics attributed to bone marrow stromal cells in vivo (Ashton et al., 1985; Owen, 1988) . In cultures generated from single-cell suspensions of marrow, colonies are formed, each derived from a single precursor cell termed the colony-forming-unit fibroblast (CFU-F) Latsinik et al, 1986) , and the progeny of these CFU-F are what we define here as bone marrow stromal cells (BMSCs). When marrow cells are plated at higher densities, the colonies merge early and BMSCs grow as monolayers Due to a high proliferation potential, BMSCs can be expanded in culture to greater than a billion nucleated cells from a limited starting sample of I mL of a Bone human bone marrow aspirate, or from the contents of the long bones of a guinea pig, 4 rat, mouse, or rabbit (Friedenstein, 1980) . Isolation of relatively pure BMSC cultures can be attained after subculture, however, the degree of purification may be dependent on the species and strain of animal used. Contamination with hematopoietic cells is higher in mouse BMSC strains than human BMSCs, and is diminished during consecutive passages in vitro (Krebsbach et al, 1997; Kuznetsov et al, 1997b) Fei et al, 1990; Song et al, 1995;  ability to form Zhang et al, 1995) . After extended culture, adipocytes. Adc BMSCs maintain the ability to form bone, strated that the cartilage, fibrous tissue, hematopoiesis-one type to ano supporting reticular stroma and associated such, this populi adipocytes, and perhaps muscle (Fig. 1) . and in disease s Thus, the BMSC population contains pre-of which was dc cursor cells capable of extensive proliferation and differentiation into several phenotypes , Ashton et al., 1980 Patt et al, 1982 , Owen, 1988 Bennett et al, 1991 (Yoshikawa et al., 1996a) .
Transplantation of BMSCs has distinct advantages over transplantation of the total marrow cell population. First, large numbers of BMSCs can be generated from a I mL marrow aspirate, thus avoiding the necessity for an additional surgery to harvest large amounts of autogenous marrow. For example, marrow harvested from long bones of a single rat provide enough cells for 2 or 3 successful bone-forming transplants, while BMSC cultures initiated by the same cell numbers provide enough cells for 50 transplants (Yoshikawa et al, 1996a) . Under appropriate conditions, BMSCs maintain their multipotential capability during prolonged cultivation and multiple passages in vitro, although it is true that a 'stem-cell"
character has never been definitively demonstrated (i e, the ability to self-renew continuously). However, the outcome of BMSC transplantation is strongly dependent on a number of cultivation and transplantation parameters, as well as on the BMSC species origin, as described below. Second, bone formation by transplanted BMSCs generally occurs more rapidly, and is more extensive than in transplants of total marrow cells (Goshima et l., 1991b; Gundle et al., 1995, Krzymanski and Wiktorledrzeiczak, 1996 (Ashton et al., 1980 (Ashton et al., , 1984 Friedenstein et al., 1987) . These results suggest that factors influencing the differentiation of multipotential BMSCs include the diffusion of nutrients and oxygenation of cells. In deeper regions of the chambers, where diffusion of nutrients and oxygen supply would likely be reduced, cartilage is formed, whereas osteogenesis proceeds in regions neighboring the membranes of the diffusion chamber, where the surrounding vasculature contributes nutrients, cell-signaling factors, and oxygen. Rabbit BMSCs expanded in vitro for as many as 17 passages have been shown to retain their osteogenic potential (Miskarova et al., 1970) . This result is not influenced by the numbers of transplanted cells (in the range of 1 x 104 to 2 x 106 BMSCs per chamber) (Friedenstein et al., 1987) . Osteogenesis by guinea pig BMSCs is more dependent on the initial cell number within the chambers, with bone formed at high cell concentrations, but only fibrous tissue formed at lower concentrations (Chailakhyan and Lalykina, 1969) . Neonatal pig BMSCs implanted at high concentrations in 2-mm-thick chambers consistently form bone, cartilage, and fibrous tissue 6-8 weeks after transplantation (Thomson et al., 1993) , while rat BMSCs are less osteogenic in the closed system and form bone only in 10% of the chambers at 8-12 weeks post-transplantation (Goshima et al., 199 lb) .
(B) BONE FORMATION IN DIFFUSION CHAMBERS SEEDED WITH HUMAN BMSCS
The osteogenic potential of human BMSCs has also been studied in diffusion chambers implanted intraperitoneally into immunocompromised mice. Interestingly, bone and cartilage formation was not detected 2-12 weeks after transplantation when the cells were cultured without dexamethasone (Ashton et al., 1985; Gundle et al., 1995) . These results were not influenced by age or gender of the donors, or by the anatomical site from which the marrow was harvested . However, if human BMSCs were cultured in the continuous presence of dexamethasone (10-8 M) prior to transplantation, they produced osteogenic tissue with active osteoblasts, and cartilage deeper into the chamber (Gundle et al., 1995 For open system transplants, the use and nature of the transplantation vehicle clearly are essential components for successful osteogenesis. Osteogenesis does not proceed when bone marrow suspensions are injected subcutaneously or intramuscularly, and when BMSCs are implanted as a cell pellet without a vehicle (Goshima et al., 199 lb; Yoshikawa et al., 1996a) , or when BMSCs are implanted into rapidly resorbed vehicles Gorsheva et al., 1981) . Thus, it is evident that, in order to form bone, transplanted BMSCs require the presence of an organized substrate in which they can adhere and proliferate for periods long enough to ensure differentiation and osteogenesis. Of the vehicles used for BMSC transplantation to date, hydroxyapatite-based constructs have emerged as the most successful.
(A) TRANSPLANTATION OF NON-HUMAN CELLS IN OPEN SYSTEMS
Bone formation by rat BMSCs was studied in subcutaneous transplants in various types of hydroxyapatite (HA)-containing ceramics in the form of disks or cubes including HA coralline ceramic (Yoshikawa et al., 1996a) , hydroxyapatite/tricalcium phosphate (HA/TCP) (Goshima et al., 1991b; Dennis et al., 1992; Dennis and Caplan, 1993) , and self-setting porous HA cement (Yoshikawa et al., 1996b) . In most transplants, extensive bone formation developed. The histologic sequence of events leading to osteogenesis was reminiscent of that described during embryonic intramembranous bone formation. After one week, pores of the ceramic vehicle were filled with proliferating mesenchymal cells. At two weeks, osteoblast-like cells lined the surface of the ceramic and deposited small amounts of bone directly onto ceramic surfaces. By four weeks, new bone covered most of the pore surfaces and was followed by bone remodeling in close association with the ingrowing vasculature. At eight weeks, marrow cavities containing a substantial amount of hematopoietic cells were formed in conjunction with the new bone (Goshima et al., 199 lb) . Bone formation started on the surface of the ceramic and advanced toward the center of the pore (Yoshikawa et al., 1996a) . In most transplants, no cartilage was found, though chondrocytes could be occasionally observed in avascular pores (Goshima et al., 1991b; Dennis et al., 1992; Dennis and Caplan, 1993) . Interestingly, ceramics pretreated with fibronectin or laminin retained twice the number of BMSCs than non-treated ones, and led to more rapid osteogenesis than non-treated vehicles (2 weeks vs. 4 weeks). In addition, more transplants in HA/TCP ceramic were positive for bone than in coralbased ceramic (Dennis et al., 1992; Dennis and Caplan, 1993) . By means of a more typical tissue engineering strategy, it was shown that bone formation could be accelerated if rat BMSCs were precultured within HAcontaining vehicles for two weeks prior to transplantation (Yoshikawa et al., 1996a) . This approach could be promising for clinical applications of autogenous BMSCs and deserves further investigation for human cells.
Bone and bone marrow were formed by rat BMSCs that were cultured for four weeks on a type I collagen matrix prior to transplantation. In these experiments, the cells had an opportunity to synthesize a matrix within the vehicle. If BMSCs had been cultured on the collagen matrix for only two days, the collagen matrix was rapidly resorbed, no bone formed after transplantation, and fat tissue developed instead (Mizuno et al., 1997) . These data emphasize that, for successful bone formation by BMSCs that have been cultured in vitro, the transplanted vehicle should be sustained in vivo for at least several weeks to allow for adequate proliferation and differentiation necessary for the initiation of osteogenesis. If the vehicle is resorbed prior to these events, such as is the case for certain types of collagen matrices, bone formation will not ensue. Some success with resorbable vehicles has been reported for transplants of rat BMSCs in poly(DL-lacticco-glycolic acid) foam. After a one-week in vitro culture period in which rat BMSCs were able to proliferate and establish an extracellular matrix within poly(DL-lacticco-glycolic acid) foams, transplants were placed into the rat mesentery (Ishaug-Riley et al., 1997) . Ectopic bone was formed as early as one week post-transplantation; however, the mineralized tissue penetrated only about 200 to 400 microns into the polymer implant. Considered collectively, these data suggest that the successful use of rapidly resorbing vehicles may require an in vitro growth period to allow BMSCs to organize an extracellular matrix so that a BMSC network primed for osteogenesis will be implanted.
Mouse BMSCs have been transplanted in collagen sponges under the kidney capsule of syngeneic recipients. Ossicles containing bone marrow were developed in most transplants by 4-5 weeks, and they were maintained for at least five months Friedenstein et al., 1982; Kuznetsov et al., 1989) . When mouse BMSCs were transplanted subcutaneously into immunocompromised recipients, they formed bone complete with hematopoietic tissue in all vehicles tested: collagen sponges, collagen matrices, polyvinyl sponges, HA/TCP blocks, and HA/TCP powder (Krebsbach et al., 1997) . In collagen sponges, the new bone appeared as early as two weeks post-transplantation. At four weeks, a cortical-like bone capsule developed surrounding an area with active hematopoiesis. The bone marrow tissue included reticular and adipocytic stroma, and hematopoietic cells of all lineages and stages of maturation, including colony-forming cells, in numbers equivalent to those of skeletal marrow. Both bone and hematopoietic tissue showed no signs of degeneration or senescence for at least 14 weeks posttransplantation (Krebsbach et al., 1997) and, thus, could be considered self-maintained.
Rabbit BMSCs were transplanted autogenously under the kidney capsule inside Plexiglas rings. Heterotopic ossicles were formed in all 45-90-day-old transplants. Interestingly, the nature of the associated marrow tissue mirrored the original bone marrow from which BMSC cultures had been initiated. BMSCs cultured from cellular (red) marrow produced a stroma with numerous hematopoietic foci, whereas those cultured from a hypocellular (yellow) marrow produced a stroma replete with fat cells (Patt et al., 1982) . These important data imply that rabbit BMSCs "remember" their origin during numerous passages in vitro and after in vivo implantation, and recreate the structure of their original tissue. it would be interesting to study whether using chromosomal markers, mouse strain-specific antiserum, species-specific antibodies, and reverse transplantation have shown that in heterotopic transplants of either rodent marrow cells or BMSCs, bone-forming cells are of donor origin. By similar criteria, hematopoietic cells and macrophages originate from the recipient (Friedenstein et al., 1968 Hotta et al., 1983) In transplants of BMSCs derived from transgenic mice bearing a type collagen-chloramphenicol acetyltransferase (CAT) reporter gene, cells within the newly formed bone displayed CAT activity up to at least 14 weeks post-transplantation (Krebsbach et al., 1997) , providing yet another method to follow the fate of the transplanted cells In one report, transplants of quail marrow into nude mice showed a biphasic switch in the origin of new bone-forming cells (Goshima etal., 1991a) Okumura, 1990, Haynesworth et al., 1992; Gundle et al., 1995; Martin et al., 1997) Figure 3 . Heterogeneity of the osteogenic capacity of clonally derived human bone marrow stromal cells demonstrated by in vivo transplantation. Individual clones, arising from the proliferation of a single CFU-F, were isolated from low-density cultures of human bone marrow cell suspensions and expanded in culture in order to generate enough cells for transplantation. Cells were attached to ceramic particles or adsorbed to CollagrahfTM as vehicles (V), and transplanted subcutaneously into immunocompromised mice. Transplants were harvested 6 weeks later and histologically analyzed. In some clones, only fibrous tissue (F) was formed (a), while in other clones fibrous tissue (F) along with low levels of bone (B) were formed (b). In other clones, larger amounts of bone were formed, but hematopoiesis was absent (c). Approximately 24% of the clones formed bone and supported hematopoiesis (HP) (d, e). In some cases (e), the clone was entirely equivalent to a multi-colony-derived strain (f) in the amount of bone and HP formed in the ossicle.
methasone. No bone formation was observed in tbe polyvinyl sponges, poly(L-lactic acid), and human demineralized bone matrix (Krebsbach et al., 1997 (Krebsbach et 6il., 1997 . It should be noted that HA/TCP blocks (cubes or disks) used in the majority of these studies proved to be less satisfactory for transplantation of human BMSCs than either HA/TCP powder (with or without secondary vehicle) or CollagraftTM. There is no reliable way to load cells into ceramic blocks (Dennis et al., 1992) . Whatever method is used (negative pressure, direct cell suction, etc.), only a small portion of the cell suspension can find its way into the vehicle, mostly into peripheral pores. As a consequence, bone formation is usually limited to the periphery of the transplants. Moreover, there is no simple way to determine how many cells were actually loaded into the ceramic block. Specially designed experiments with 3H-thymidinelabeled cell quantitation have shown that between 45,000 and 65,000 cells are loaded per 27 mm3 block when the cell suspension contains 5 x 106 cells/mL (Dennis et al., 1992) . In contrast, ceramic powder can be quantitatively loaded by slow rotation of the cell/vehicle mixture; this method is based on the high adhesive properties of BMSCs. As a result, more than 80% of total cells can be loaded, cells are distributed more evenly throughout the vehicle, and osteogenesis is more extensive (Krebsbach et al., 1997) . In transplants of human BMSCs in ceramic powder, bone and hematopoietic tissue showed no signs of degeneration or senescence for at least 45 weeks posttransplantation . Consequently, the newly formed heterotopic bone and hematopoietic microenvironment are self-maintained (Fig. 2) .
In 4-8-week-old transplants of human BMSCs into immunocompromised mice or rats, three different human-specific antibodies reacted with osteocytes and osteoblasts of the new bone, but not with surrounding recipient tissues Krebsbach et al., 1997; Martin et al., 1997) . In transplants of human BMSCs, cells of the new bone were immunodetected with antibodies raised against human osteonectin and expressed human-specific alu sequences for at least 45 weeks post-transplantation . These data indicate that, in heterotopic transplants of human BMSCs into an open system, as in transplants of rodent BMSCs, new bone maintains the donor origin. On the contrary, hematopoietic cells associated with the new bone are of recipient origin ).
(C) TRANSPLANTATION OF CLONAL BMSC STRAINS
As previously mentioned, when marrow cells are plated at low cell densities, BMSCs grow as discrete colonies, each formed by proliferation of a single CFU-F (Friedenstein etal., 1978; Latsiniket al., 1986) . The studies reviewed above have used multi-colony-derived strains consisting of descendants of multiple BMSC coloniesi.e., many CFU-Fs. However, to analyze the natural heterogeneity of a CFU-F population, one must study descendants of individual CFU-Fs. About 20% of the colonies formed bone when individual colonies of mouse or guinea pig BMSCs were transplanted . When rabbit single-colonyderived BMSC strains were transplanted into diffusion chambers, either autogenously or into immunocompromised mice, bone was formed by 48.3% (Gerasimov et al., 1986; Friedenstein et al., 1987) and 36.8% of the strains (Bennett et al., 1991) , respectively.
Human single-colony-derived BMSC strains from four donors were transplanted into immunodeficient mice in HA/TCP powder and Collagraft. After eight weeks, 20 out of 34 strains (58.8%) formed bone, and the remainder formed only fibrous tissue. Among the 20 positive strains, eight formed extensive bone accompanied by hematopoietic tissue (23.5%), and 12 formed less abundant bone without hematopoiesis (35.3%) (Fig. 3 ). These data demonstrate that individual CFU-Fs are capable of forming both bone and a supportive hematopoietic microenvironment. They also demonstrate that the CFU-F population is heterogeneous and that only a fraction of it consists of multipotential cells that have the ability to differentiate sequentially into several tissues, including bone and hematopoiesis-supportive stroma with associated adipocytes.
(VI) Factors Influencing Bone Formation in Open System Transplants of BMSCs
Many of the factors that influence osteogenesis by BMSCs have been discussed above and include the species origin of BMSCs, the composition of the transplantation vehicle, and the method by which cells are loaded into the vehicle. It is likely, however, that several other factors participate to accelerate or impede osteogenesis by transplanted BMSCs. Among these potential modifiers are: (1) the optimum in vitro cell expansion conditions, (2) the cell seeding density, and (3) the ideal vehicle composition. Other factors-such as the cryopreservation of BMSCs before transplantation and the origin of marrow (age and gender of donor, skeletal location, method of marrow extraction)-show no obvious correlation with frequency or extent of bone formation (Goshima et al., 199 lb; Haynesworth et al., 1992; Bruder et al., 1997a; Krebsbach et al., 1997) . The number of in vitro passages and population doublings of the BMSCs before transplantation did not affect bone formation as long as the cells retained their proliferative status. However, mouse BMSCs of the 13th passage that had ceased to proliferate in vitro did not form bone in vivo (Krebsbach et al., 1997) . Rat BMSCs formed bone for up to 18 passages. However, osteogenesis was delayed and the rate of bone formation declined with increasing passage number (Goshima et al., 1991a) . In an extensive in vitro study, it was demonstrated that cultured BMSCs derived from human iliac crest aspirates average about 38 population doublings before becoming senescent, and despite reaching a point of senescence, the cells remained capable of osteogenesis (Bruder et al., 1997b) .
To date, the dependence of in vivo bone formation on the number of transplanted BMSCs has not been systematically studied. When mouse BMSCs are transplanted under the kidney capsule in collagen sponges, ossicles containing bone marrow are formed in most of the transplants containing from 1 x 105 to 2 x 106 BMSCs, but not in transplants containing fewer than 0.5 x 105 BMSCs Friedenstein et al., 1982) . Only those ceramics (27 mm3 cubes) that retain greater than 3 x 104 rat BMSCs per transplant consistently form bone (Dennis et al., 1992; Dennis and Caplan, 1993) . Cell number may not influence the extent of bone formation throughout the range of 1.5 to 16 x 106 mouse or human BMSCs per transplant (20-100 mm3 vehicle volume) (Krebsbach et al., 1997) . However, in light of the abovementioned studies, these transplants likely exceeded the threshold necessary for osteogenesis. Thus, it is evident that the minimum number of BMSCs necessary for bone formation after implantation is yet to be determined.
Medium composition can also significantly affect bone formation by transplanted BMSCs. Specifically, selected lots of serum appear to be particularly important for growth of BMSCs from rodent species; however, the factors that are present in various amounts from one lot of serum to another have not been delineated. For mouse BMSCs, the presence of dexamethasone in culture medium did not influence the extent of bone formation (Krebsbach et al., 1997) . Similar observations were noted with human BMSCs transplanted into HA/TCPcontaining vehicles (Gundle et al., 1995; Krebsbach et al., 1997; Kuznetsov et al., 1997b) . However, human BMSCs transplanted into diffusion chambers or collagen sponges formed bone only after cultivation in medium that included dexamethasone (Gundle et al., 1995; Krebsbach et al., 1997) . In addition, when low numbers of human BMSCs were transplanted (2.5 x 105 per 64 mm3 HA ceramic cube), cultivation with dexamethasone increased the extent of bone formation (Martin et al., 1997) . Rat BMSCs transplanted into coralline HA ceramic cubes formed bone only after cultivation with dexamethasone (Yoshikawa et al., 1996a) .
The effects of several growth factors on bone formation by transplanted BMSCs have also been studied. PDGF-BB (5 ng/mL, present for 48 hrs before transplantation) did not change the in vivo bone formation by rat BMSCs, while TGF-3 decreased bone formation in 50% of the experiments under similar conditions (Cassiede et al., 1996) . Six-day pretreatment with BMP-2 (50 ng/mL) did not stimulate bone formation by rat BMSCs, while pretreatment with bFGF (2.5 ng/mL) enhanced bone formation, which was further enhanced by a combination of bFGF with BMP-2 (Hanada et al., 1997) . Human BMSCs grown in the presence of FGF-2 (1 and 10 ng/mL) yielded significantly greater bone formation than those grown without it, while other growth factors, including PDGF, EGF, IGF-1, TGF-31, and GH, did not affect the extent of bone formation (Martin et al., 1997 (199) ritRevOralBio Me 17 face of the medial femoral condyle. As early as two weeks post-transplantation, the transplanted cells differentiated into chondrocytes in the upper half of the defect; the deeper half was filled with newly formed cancellous bone. At 24 weeks, the subchondral bone was completely repaired, without loss of overlying articular cartilage. The cartilage surface remained smooth, although the cartilage became thin. In cell-free controls, there was substantially less repair. Mechanically, the reparative tissue was stiffer than in cell-free controls, but less stiff than normal cartilage (Wakitani et al., 1994) .
Autogenous canine BMSCs were loaded into fibronectin-coated HA/TCP cylinders and transplanted into 21-mm-long segmental femoral mid-diaphyseal defects. Rapid bone formation occurred at all hostimplant interfaces, resulting in union of all animals by eight weeks. A substantial collar of bone developed surrounding the implant itself; after 12 weeks, the callus began to remodel to the original dimension of the implant. Animals whose defects were not filled formed a fibrous non-union. If cell-free vehicles were implanted, bony ingrowth was limited to the interface, and the bulk of the implant was devoid of bone. Cancellous bone from the iliac crest was also transplanted to some defects; these transplants were radiographically equivalent to the BMSC-based ones (Bruder et al., 1998b,c) .
(C) HUMAN STUDIES
In humans, blood and bone marrow are the most frequently transplanted materials (Allard et al., 1987; Pedrosa et at., 1989; Aglietti et al., 1991; Eggers and Meeder, 1994; Friend et al., 1995; Olsen et al., 1995; Arrington et al., 1996; Bradbury et al., 1996) . Fresh autogenous bone grafts are preferred in orthotopic procedures because of their compatibility and efficacy. In addition, autogenous grafts are able to trigger direct osteogenesis by bone cells. Autogenous iliac bone is considered to have the highest osteogenic potential, and indeed, the osteogenic potential has been shown to reside within the marrow stromal compartment. This is supported by the clinical observation that autogenous bone impregnated with red marrow has a beneficial effect on osteogenesis. However, the amount and quality of implanted bone needed limit the use of autogenous bone alone. Large defects may require a larger amount of bone than is available for harvesting (Arrington et at., 1996) . In addition, if the quality of bone is poor, such as in certain disease states, the autogenous bone may not be appropriate for engraftment. These limitations point to the real need for the development of procedures that use ex vivo expanded BMSCs.
Experiments where human BMSCs are transplanted orthotopically into animal recipients represent an intermediate step between ectopic animal transplantation and orthotopic transplantation into human patients.
Human BMSCs of the 2nd passage were loaded into fibronectin-coated HA/TCP cylinders and transplanted into 8 mm central diaphyseal defects of athymic rats. By 12 weeks, 47% of implant volume was filled with bone of human origin; control transplants of empty vehicles contained 27% bone. Also, stiffness and failure load of BMSC-loaded implants was significantly greater than those of cell-free implants (Bruder et al., 1997c (Bruder et al., , 1998c (Krzymanski and Wiktor-ledrzejczak, 1996 (Storm et at., 1996) . A preliminary study in mice has shown that ex vivo expanded BMSCs can be used to generate bone sur-rounding an isolated artery and vein. BMSCs in vehicle were wrapped around the internal carotid artery and inferior jugular vein, and further encircled with an expanded polytetrafluoroethylene membrane (GoretexTM) to prevent collateral vascularization. After eight weeks, the transplant contained cortical and cancellous bone fully perfused by the artery and vein. This technique shows a great deal of promise for reconstructive surgery such that a vascularized bone graft can be generated within the patient's own body and then relocated to a recipient site as needed (Mankani et al., 1997b) .
(E) SYSTEMIC DISTRIBUTION OF BMSCS The methodologies described above are very applicable to the restoration of segmental bone defects. However, in cases of generalized bone loss such as in a variety of skeletal diseases including osteoporosis, osteogenesis imperfecta, etc., it is not feasible to consider direct transplantation into all affected bones. In these cases, it would be desirable to inject BMSCs for distribution via the circulatory system such that they would be widely dispersed, and stimulated in some fashion to regenerate new (and/or better) bone.
Injection of marrow stromal cells has been attempted in both animal models and in humans, with limited success. There are numerous reports that stromal cells present in the cell population injected during bone marrow transplantation procedures do not survive their travels in the circulation, and do not repopulate bone or any other tissue (Friedenstein and Kuralesova, 1971; Friedenstein et al., 1978; Wilson et al., 1978; Golde et al., 1980; Chertkov et al., 1985; Laver et al., 1987; Ma et al., 1987; Simmons et al., 1987; Raskind et al., 1988; Athanasou et al, 1990; Ribera et al., 1990; Agematsu and Nakahori, 1991; Santucci etal., 1992) . However, when partially purified bone marrow stromal cells isolated from transgenic mice expressing a human mini-gene for collagen type I as a marker were injected into irradiated mice, polymerase chain-reaction assays for the collagen minigene indicated that, after 1-5 months, the donor cells accounted for 1.5-12% of the cells in bone, cartilage, and lung in addition to marrow and spleen (Pereira et al., 1995) . In other studies, an immortalized marrow stromal cell line engineered to express ,B-galactosidase was also found in bone after injection (Dahir et al., 1996) . These results suggest that BMSCs expanded in culture may serve as long-lasting precursors of bone, cartilage, and lung. However, it should be noted that in the first study, the marrow stromal cells were likely contaminated with macrophages which may engraft easily, and in the second case, the cells used were immortalized, which may represent a selective advantage to survival in the circulatory system compared with non-immortalized, normal cells. In a recent report, Pereira and colleagues showed that infusion of marrow stromal cells from wild-type mice could partially rescue a phenotype of fragile bones resembling osteogenesis imperfecta (Pereira et al., 1998) . DNA from the donor marrow stromal cells was detected consistently in marrow, bone, cartilage, and lung either one or 2.5 months after the infusions, suggesting that marrow stromal cells or related cells in marrow may serve as a source for continual renewal of cells in a number of nonhematopoietic tissues.
The route of injection may also influence the survival of injected BMSCs (Mankani et al., 1997b) . If injected via the tail vein, BMSCs were removed primarily by the lungs, and if injected via the left ventricle, the distribution was somewhat broader but still did not result in localization of the BMSCs to bone or bone marrow. Only when the cells were injected into the abdominal carotid arteries were significant levels of BMSCs identified in bone marrow, in addition to skin, muscle, and spleen. However, it has not yet been demonstrated that these cells survive long term and actually engraft.
Several human patients have been transfused with ex vivo expanded BMSCs (Lazarus et al., 1995) (Sakai et al., 1996; Grassi et al., 1997) . It (Allay et al., 1997) .
(G) ANIMAL MODELS OF HUMAN BONE DISORDERS
The observation that BMSCs are osteogenic precursors capable of recreating the architecture of their original tissue gave rise to the hypothesis that transplanted BMSCs may recapitulate the pathophysiology of skeletal disease, thus creating an in vivo model of skeletal disorders. So far, this assumption has been proved true for the McCune-Albright Syndrome (MAS). McCune-Albright Syndrome is a non-inherited genetic disease caused by activating missense mutations of the gene encoding the cx subunit of the stimulating G protein. MAS is a mosaic disorder whose manifestations include endocrinopathies, skin hyperpigmentation, and polyostotic fibrous dysplasia of bone. When BMSC colonies from MAS patients were cultured, they were found to be of two types: normal (cells contained two normal Gsx alleles) and mutant (one normal allele and one with mutation). Subcutaneous transplantation of normal BMSCs into immunocompromised mice resulted in the formation of normal ossicles, while transplantation of mutant cells alone led to the loss of transplanted cells with no ossicle formation. However, transplantation of a mixture of normal and mutant cells reproduced an abnormal ectopic ossicle recapitulating many features of human fibrous dysplasia (Bianco et al., 1998) . These data provide additional insight into the pathophysiology of fibrous dysplasia in MAS and offer a novel approach to the study of the disease and potential therapeutic interventions. More generally, transplantation of pathologic BMSCs in vivo may provide a promising strategy for generating animal models of other human bone disorders.
(Vill) Future Directions While our understanding of the nature of BMSCs has been greatly expanded during recent years, it is clear that there is still much to be learned about these important mediators of skeletal metabolism, and that their further characterization is crucial for their clinical application. Questions that remain unanswered include: (1) What is the in vivo identity of the CFU-F, the progeny of which we have partially characterized as BMSCs in vitro? (2) How do CFU-F and their progeny participate in the processes of normal skeletal metabolism, and how are these processes changed in disease states? and (3) What are the regulatory factors that influence the activity of CFU-F and their progeny to determine which phenotype they will express, both in vivo and in vitro?
If these questions are to be answered, it is clear that better identification of CFU-Fs and BMSCs must be made, both in vivo and in vitro. To date, there is only a handful of markers (as identified by monoclonal antibodies) that appear to be specific for these cells (Akasaka et al., 1991; Simmons and Torok-Storb, 1991; Benayahu et al., 1995; Masuhara et al., 1995; Bruder et al., 1997a) . For the most part, the antigens recognized by these antibodies have not been well-characterized, and their absolute specificity is not clear. A recent discovery that may assist in the purification of "potential stem cells" within the BMSC population is the finding that a monoclonal antibody (SB-10) recognizes the activated leukocyte-cell adhesion molecule (ALCAM) (Bruder et al., 1998a) . Because ALCAM is expressed on human BMSCs but is lost during developmental progression into differentiated tissues, SB-10 will likely be an important experimental tool for the study of osteoblast cell lineage. Through the use of new molecular biological technologies-such as subtractive hybridizations, differential display, SAGE (serial analysis of gene expression), and microarray technologies-it is hoped that new genes that are uniquely expressed by these cells will be identified. At the very least, should unique markers remain elusive, a pattern of gene expression, a so-called "fingerprint", will be generated through these types of analyses. With this information, development of reagents and screening strategies would allow for the identification of stem cells in vivo and the potential for cell sorting and further analysis in vitro.
A major gap in our knowledge relates to the fact that the true "stem-cell" character of BMSCs (i.e., continuous self-renewal) has not been definitively proven in any animal species. If there is a true "stem-cell" present in this population, it will be necessary to determine the appropriate ex vivo culture conditions that will maintain their stem cell character (as has been done for embryonic stem cells used in the generation of transgenic animals), and then to induce them to differentiate into the desired phenotype through the modulation of their microenvironment, both in vivo and in vitro. Consequently, a better understanding of the hierarchy of CFU-Fs and BMSCs is needed. While it is now recognized that these popula-tions display a variety of phenotypic expression patterns (osteoblastic, chondrogenic, hematopoiesis-supportive, adipocytic) both in vivo and in vitro, it is not understood how this phenotypic heterogeneity is established, maintained, and disrupted in disease states.
Animal studies have provided a great deal of encouragement; however, there are several obstacles that must be overcome prior to the use of BMSCs in human clinical protocols. First, large quantities of ex vivo expanded cells must be generated in an FDA-approved tissue culture facility in order to provide enough material for reconstruction of typically large skeletal segmental defects. True utility of BMSCs in skeletal regeneration will require major improvements in the current ex vivo expansion procedures to increase the yield and reduce the time required to generate sufficient numbers of cells. Given the inherent heterogeneity of the BMSC population, it may also be required to develop large-scale cloning procedures such that clones with desired phenotypic characteristics can be purified and used directly in tissue engineering protocols. For example, in the regeneration of craniofacial bones, which are primarily devoid of hematopoietic marrow, BMSCs clones that give rise only to bone without hematopoiesis would be more desirable than the use of multi-colony-derived strains that would generate bone along with hematopoietic stroma.
Second, there is a need for continued development of vehicles for the introduction and engraftment of these cells in vivo. Appropriate vehicles must be engineered and carefully selected depending on the site to be reconstructed (weight-bearing vs. non-weight-bearing sites, trabecular vs. cortical sites, etc.). It is likely that reconstruction of a particular skeletal site will require different vehicles, with or without bioactive factors, designed to direct the activity of BMSCs into specific expression patterns to regenerate bone in the desired shape and form.
Finally, if the use of BMSCs in gene therapy protocols is to be successful, better methods for stably or transiently transfecting normal human cells with high efficiency are critical. It can be envisioned that BMSCs can be either transiently or stably transfected to produce a protein that is missing or defective, and implanted within a patient to provide a missing or defective protein. However, expression of the desired protein product must be controlled such that the level of its production, posttranslational modification, secretion, and localization to the desired active site is suitable. Selection of the appropriate promoter driving the ectopic production of the desired protein is of critical importance for physiologically significant expression and secretion and will require extensive knowledge of gene expression patterns on the part of the implant team.
While it is clear that there is much yet to be learned, it is also clear that the BMSC population provides a unique scientific opportunity for us not only to better our understanding of the processes of skeletal metabolism and homeostasis, but also to translate this information into clinical procedures that will provide a great deal of patient benefit.
